Stifel Nicolaus Cuts LivaNova (NASDAQ:LIVN) Price Target to $60.00

LivaNova (NASDAQ:LIVN) had its target price decreased by Stifel Nicolaus from $72.00 to $60.00 in a research note published on Wednesday morning,Benzinga reports. Stifel Nicolaus currently has a buy rating on the stock.

A number of other analysts have also weighed in on LIVN. Robert W. Baird increased their price objective on LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. StockNews.com raised shares of LivaNova from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 14th. Needham & Company LLC cut their price target on shares of LivaNova from $75.00 to $64.00 and set a “buy” rating on the stock in a report on Wednesday. Wolfe Research downgraded shares of LivaNova from an “outperform” rating to a “peer perform” rating in a research note on Wednesday. Finally, Mizuho cut their target price on LivaNova from $80.00 to $70.00 and set an “outperform” rating on the stock in a research note on Thursday, October 31st. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $64.20.

LivaNova Trading Up 1.7 %

Shares of LIVN stock opened at $41.63 on Wednesday. The business has a 50-day moving average of $47.40 and a 200 day moving average of $49.49. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. LivaNova has a 1-year low of $40.37 and a 1-year high of $64.47. The stock has a market capitalization of $2.26 billion, a PE ratio of 99.12 and a beta of 1.00.

Insider Activity

In related news, Director Francesco Bianchi sold 1,250 shares of the stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total value of $63,737.50. Following the completion of the transaction, the director now directly owns 7,522 shares of the company’s stock, valued at $383,546.78. This represents a 14.25 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 0.27% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Russell Investments Group Ltd. boosted its position in shares of LivaNova by 17.1% during the fourth quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company’s stock valued at $70,000 after purchasing an additional 219 shares in the last quarter. Sterling Capital Management LLC lifted its position in LivaNova by 800.6% during the fourth quarter. Sterling Capital Management LLC now owns 1,621 shares of the company’s stock valued at $75,000 after buying an additional 1,441 shares during the period. Central Pacific Bank Trust Division boosted its holdings in shares of LivaNova by 21.2% during the 4th quarter. Central Pacific Bank Trust Division now owns 4,117 shares of the company’s stock valued at $191,000 after buying an additional 720 shares in the last quarter. Vestcor Inc purchased a new stake in shares of LivaNova in the 4th quarter worth about $204,000. Finally, Optimize Financial Inc bought a new position in shares of LivaNova in the 4th quarter worth about $208,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.